LP
NGM

Lexington Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Lexington Partners’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-110,428
Closed -$1.42M – 8
2022
Q2 		$1.42M Buy
+110,428
New +$1.53M 0.73% 7

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Lexington Partners's NGM Position: Q3 2022 in Review

Lexington Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2022, closing a stake of 110,428 shares — an estimated $1.42M sold.

Lexington Partners first reported a position in NGM in Q2 2022 and held it in 1 quarter. The position peaked at $1.42M in Q2 2022. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

  • Lexington Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Lexington Partners sold 110,428 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $1.42M.
  • Lexington Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Lexington Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.42M in Q2 2022.
  • 128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Lexington Partners's 13F filing for Q3 2022, filed 14 Nov 2022.